Target-responsive DNA/RNA nanomaterials for microRNA sensing and inhibition: The jack-of-all-trades in cancer nanotheranostics?

Advanced Drug Delivery Reviews

Volumn 81, Issue , 2015, Pages 169-183

  Conde, João ^a   Edelman, Elazer R ^a,b   Artzi, Natalie ^a,b  

^a Massachusetts Institute of Technology Cambridge   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Biosensors; Cancer; MicroRNA; Nanomaterials; Nanotheranostics; RNAi; Surface modification; Translational medicine

Indexed keywords

BIOSENSORS; DISEASES; NANOSTRUCTURED MATERIALS; SURFACE TREATMENT;

CANCER; MICRORNAS; NANOTHERANOSTICS; RNAI; TRANSLATIONAL MEDICINE;

RNA;

DNA; GRAPHENE OXIDE; MESSENGER RNA; MICRORNA; NANOMATERIAL; PLASMID DNA; RNA;

CANCER THERAPY; ELECTROCHEMISTRY; GENE EXPRESSION; GENE SILENCING; GENE VECTOR; NANOENCAPSULATION; NANOMEDICINE; NANOSENSOR; NANOTHERANOSTIC; REVIEW; RNA ANALYSIS; RNA DEGRADATION; TUMOR SUPPRESSOR GENE; ANIMAL; GENE TRANSFER; GENETICS; HUMAN; NEOPLASMS;

ANIMALS; DNA; GENE SILENCING; GENE TRANSFER TECHNIQUES; HUMANS; MICRORNAS; NANOSTRUCTURES; NEOPLASMS; RNA;

EID: 84922220101     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2014.09.003     Document Type: Review

References (150)

1. Fire A., Xu S., Montgomery M.K., Kostas S.A., Driver S.E., Mello C.C. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998, 391:806-811.
2. Baulcombe D. RNA silencing. Trends Biochem. Sci. 2005, 30:290-293.
3. Baker M. RNA interference: from tools to therapies. Nature 2010, 464:1225.
4. Ulitsky I., Bartel D.P. lincRNAs: genomics, evolution, and mechanisms. Cell 2013, 154:26-46.
5. Ghildiyal M., Zamore P.D. Small silencing RNAs: an expanding universe. Nat. Rev. Genet. 2009, 10:94-108.
6. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
7. Tay Y., Zhang J.Q., Thomson A.M., Lim B., Rigoutsos I. MicroRNAs to Nanog, Oct4 and Sox2 coding regions modulate embryonic stem cell differentiation. Nature 2008, 455:1124-1128.
8. Place R.F., Li L.C., Pookot D., Noonan E.J., Dahiya R. MicroRNA-373 induces expression of genes with complementary promoter sequences. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:1608-1613.
9. Peschansky V.J., Wahlestedt C. Non-coding RNAs as direct and indirect modulators of epigenetic regulation. Epigenetics 2014, 9:3-12.
10. Cesana M., Cacchiarelli D., Legnini I., Santini T., Sthandier O., Chinappi M., Tramontano A., Bozzoni I. A long noncoding RNA controls muscle differentiation by functioning as a competing endogenous RNA. Cell 2011, 147:358-369.
11. Milhavet O., Gary D.S., Mattson M.P. RNA interference in biology and medicine. Pharmacol. Rev. 2003, 55:629-648.
12. Pai S.I., Lin Y.Y., Macaes B., Meneshian A., Hung C.F., Wu T.C. Prospects of RNA interference therapy for cancer. Gene Ther. 2006, 13:464-477.
13. Carthew R.W., Sontheimer E.J. Origins and mechanisms of miRNAs and siRNAs. Cell 2009, 136:642-655.
14. Paranjape T., Slack F.J., Weidhaas J.B. MicroRNAs: tools for cancer diagnostics. Gut 2009, 58:1546-1554.
15. Cifuentes D., Xue H.L., Taylor D.W., Patnode H., Mishima Y., Cheloufi S., Ma E.B., Mane S., Hannon G.J., Lawson N.D., Wolfe S.A., Giraldez A.J. A novel miRNA processing pathway independent of dicer requires Argonaute2 catalytic activity. Science 2010, 328:1694-1698.
16. Cheloufi S., dos Santos C.O., Chong M.M.W., Hannon G.J. A Dicer-independent miRNA biogenesis pathway that requires Ago catalysis. Nature 2010, 465:584-U76.
17. Ketting R.F. Partners in dicing. Genome Biol. 2006, 7:1-4.
18. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J. Clin. 2012, 62:10-29.
19. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
20. Collins I., Workman P. New approaches to molecular cancer therapeutics. Nat. Chem. Biol. 2006, 2:689-700.
21. McCormick F. Cancer gene therapy: fringe or cutting edge?. Nat. Rev. Cancer 2001, 1:130-141.
22. Ferracin M., Veronese A., Negrini M. Micromarkers: miRNAs in cancer diagnosis and prognosis. Expert. Rev. Mol. Diagn. 2010, 10:297-308.
23. Corsini L.R., Bronte G., Terrasi M., Amodeo V., Fanale D., Fiorentino E., Cicero G., Bazan V., Russo A. The role of microRNAs in cancer: diagnostic and prognostic biomarkers and targets of therapies. Expert Opin. Ther. Targets 2012, 16:S103-S109.
24. Zhang B.H., Pan X.P., Cobb G.P., Anderson T.A. microRNAs as oncogenes and tumor suppressors. Dev. Biol. 2007, 302:1-12.
25. Nicoloso M.S., Spizzo R., Shimizu M., Rossi S., Calin G.A. MicroRNAs-the micro steering wheel of tumour metastases. Nat. Rev. Cancer 2009, 9:293-302.
26. Kasinski A.L., Slack F.J. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat. Rev. Cancer 2011, 11:849-864.
27. de Planell-Saguer M., Rodicio M.C. Analytical aspects of microRNA in diagnostics: a review. Anal. Chim. Acta. 2011, 699:134-152.
28. Li Z., Rana T.M. Therapeutic targeting of microRNAs: current status and future challenges. Nat. Rev. Drug Discov. 2014, 13:622-638.
29. Cho W.C. MicroRNAs in cancer - from research to therapy. Biochim. Biophys. Acta 2010, 1805:209-217.
30. Cho W.C. Circulating microRNAs as minimally invasive biomarkers for cancer theragnosis and prognosis. Front. Genet. 2011, 2:7.
31. Bushati N., Cohen S.M. microRNA functions. Annu. Rev. Cell Dev. Biol. 2007, 23:175-205.
32. Esau C.C., Monia B.P. Therapeutic potential for microRNAs. Adv. Drug Deliv. Rev. 2007, 59:101-114.
33. Corte H., Manceau G., Blons H., Laurent-Puig P. MicroRNA and colorectal cancer. Dig. Liver Dis. 2012, 44:195-200.
34. Catto J.W.F., Alcaraz A., Bjartell A.S., White R.D., Evans C.P., Fussel S., Hamdy F.C., Kallioniemi O., Mengual L., Schlomm T., Visakorpi T. MicroRNA in prostate, bladder, and kidney cancer: a systematic review. Eur. Urol. 2011, 59:671-681.
35. Koshiol J., Wang E., Zhao Y.D., Marincola F., Landi M.T. Strengths and limitations of laboratory procedures for microRNA detection. Cancer Epidemiol. Biomark. Prev. 2010, 19:907-911.
36. Hou S.Y., Hsiao Y.L., Lin M.S., Yen C.C., Chang C.S. MicroRNA detection using lateral flow nucleic acid strips with gold nanoparticles. Talanta 2012, 99:375-379.
37. Conde J., Rosa J., de la Fuente J.M., Baptista P.V. Gold-nanobeacons for simultaneous gene specific silencing and intracellular tracking of the silencing events. Biomaterials 2013, 34:2516-2523.
38. Yang W.J., Li X.B., Li Y.Y., Zhao L.F., He W.L., Gao Y.Q., Wan Y.J., Xia W., Chen T., Zheng H., Li M., Xu S.Q. Quantification of microRNA by gold nanoparticle probes. Anal. Biochem. 2008, 376:183-188.
39. Xia X.D., Hao Y.Q., Hu S.Q., Wang J.X. Hairpin DNA probe with 5'-TCC/CCC-3' overhangs for the creation of silver nanoclusters and miRNA assay. Biosens. Bioelectron. 2014, 51:36-39.
40. Hwang D.W., Song I.C., Lee D.S., Kim S. Smart magnetic fluorescent nanoparticle imaging probes to monitor microRNAs. Small 2010, 6:81-88.
41. Zhang Y., Zhang C.Y. Sensitive detection of microRNA with isothermal amplification and a single-quantum-Dot-based nanosensor. Anal. Chem. 2012, 84:224-231.
42. Su S., Fan J.W., Xue B., Yuwen L.H., Liu X.F., Pan D., Fan C.H., Wang L.H. DNA-conjugated quantum dot nanoprobe for high-sensitivity fluorescent detection of DNA and micro-RNA. ACS Appl. Mater. Interfaces 2014, 6:1152-1157.
43. Liang R.Q., Li W., Li Y., Tan C.Y., Li J.X., Jin Y.X., Ruan K.C. An oligonucleotide microarray for microRNA expression analysis based on labeling RNA with quantum dot and nanogold probe. Nucleic Acids Res. 2005, 33.
44. Dong H.F., Zhang J., Ju H.X., Lu H.T., Wang S.Y., Jin S., Hao K.H., Du H.W., Zhang X.J. Highly sensitive multiple microRNA detection based on fluorescence quenching of graphene oxide and isothermal strand-displacement polymerase reaction. Anal. Chem. 2012, 84:4587-4593.
45. Cui L., Lin X.Y., Lin N.H., Song Y.L., Zhu Z., Chen X., Yang C.J. Graphene oxide-protected DNA probes for multiplex microRNA analysis in complex biological samples based on a cyclic enzymatic amplification method. Chem. Commun. 2012, 48:194-196.
46. Ryoo S.R., Lee J., Yeo J., Na H.K., Kim Y.K., Jang H., Lee J.H., Han S.W., Lee Y., Kim V.N., Min D.H. Quantitative and multiplexed microRNA sensing in living cells based on peptide nucleic acid and nano graphene oxide (PANGO). ACS Nano 2013, 7:5882-5891.
47. Tu Y.Q., Li W., Wu P., Zhang H., Cai C.X. Fluorescence quenching of graphene oxide integrating with the site-specific cleavage of the endonuclease for sensitive and selective MicroRNA detection. Anal. Chem. 2013, 85:2536-2542.
48. Kim E., Yang J., Park J., Kim S., Kim N.H., Yook J.I., Suh J.S., Haam S., Huh Y.M. Consecutive targetable smart nanoprobe for molecular recognition of cytoplasmic microRNA in metastatic breast cancer. ACS Nano 2012, 6:8525-8535.
49. Wang J.X., Yi X.Y., Tang H.L., Han H.X., Wu M.H., Zhou F.M. Direct quantification of microRNA at low picomolar level in sera of glioma patients using a competitive hybridization followed by amplified voltammetric detection. Anal. Chem. 2012, 84:6400-6406.
50. Peng Y.F., Gao Z.Q. Amplified detection of microRNA based on ruthenium oxide nanoparticle-initiated deposition of an insulating film. Anal. Chem. 2011, 83:820-827.
51. Peng Y.F., Yi G.S., Gao Z.Q. A highly sensitive microRNA biosensor based on ruthenium oxide nanoparticle-initiated polymerization of aniline. Chem. Commun. 2010, 46:9131-9133.
52. Gao Z.Q., Yang Z.C. Detection of microRNAs using electrocatalytic nanoparticle tags. Anal. Chem. 2006, 78:1470-1477.
53. Yin H.S., Zhou Y.L., Zhang H.X., Meng X.M., Ai S.Y. Electrochemical determination of microRNA-21 based on graphene, LNA integrated molecular beacon, AuNPs and biotin multifunctional bio bar codes and enzymatic assay system. Biosens. Bioelectron. 2012, 33:247-253.
54. Sipova H., Zhang S.L., Dudley A.M., Galas D., Wang K., Homola J. Surface plasmon resonance biosensor for rapid label-free detection of microribonucleic acid at subfemtomole level. Anal. Chem. 2010, 82:10110-10115.
55. Wang D.C., Hu L.H., Zhou H.M., Abdel-Halim E.S., Zhu J.J. Molecular beacon structure mediated rolling circle amplification for ultrasensitive electrochemical detection of microRNA based on quantum dots tagging. Electrochem. Commun. 2013, 33:80-83.
56. Tran H.V., Piro B., Reisberg S., Tran L.D., Duc H.T., Pham M.C. Label-free and reagentless electrochemical detection of microRNAs using a conducting polymer nanostructured by carbon nanotubes: application to prostate cancer biomarker miR-141. Biosens. Bioelectron. 2013, 49:164-169.
57. Wang L.Y., Cheng Y.Q., Wang H., Li Z.P. A homogeneous fluorescence sensing platform with water-soluble carbon nanoparticles for detection of microRNA and nuclease activity. Analyst 2012, 137:3667-3672.
58. Zhang G.J., Chua J.H., Chee R.E., Agarwal A., Wong S.M. Label-free direct detection of MiRNAs with silicon nanowire biosensors. Biosens. Bioelectron. 2009, 24:2504-2508.
59. Dorvel B.R., Reddy B., Go J., Guevara C.D., Salm E., Alam M.A., Bashir R. Silicon nanowires with high-k hafnium oxide dielectrics for sensitive detection of small nucleic acid oligomers. ACS Nano 2012, 6:6150-6164.
60. Fan Y., Chen X.T., Trigg A.D., Tung C.H., Kong J.M., Gao Z.Q. Detection of microRNAs using target-guided formation of conducting polymer nanowires in nanogaps. J. Am. Chem. Soc. 2007, 129:5437-5443.
61. Wang Y., Zheng D.L., Tan Q.L., Wang M.X., Gu L.Q. Nanopore-based detection of circulating microRNAs in lung cancer patients. Nat. Nanotechnol. 2011, 6:668-674.
62. Wanunu M., Dadosh T., Ray V., Jin J.M., McReynolds L., Drndic M. Rapid electronic detection of probe-specific microRNAs using thin nanopore sensors. Nat. Nanotechnol. 2010, 5:807-814.
63. Jamali A.A., Pourhassan-Moghaddam M., Dolatabadi J.E.N., Omidi Y. Nanomaterials on the road to microRNA detection with optical and electrochemical nanobiosensors. TrAC, Trends Anal. Chem. 2014, 55:24-42.
64. Conde J., Rosa J., Lima J.C., Baptista P.V. Nanophotonics for molecular diagnostics and therapy applications. Int. J. Photoenergy 2012, 2012:1-11.
65. Conde J., de la Fuente J.M., Baptista P.V. RNA quantification using gold nanoprobes - application to cancer diagnostics. J. Nanobiotechnol. 2010, 8:5.
66. Mirkin C.A., Letsinger R.L., Mucic R.C., Storhoff J.J. A DNA-based method for rationally assembling nanoparticles into macroscopic materials. Nature 1996, 382:607-609.
67. Wegman D.W., Krylov S.N. Direct miRNA-hybridization assays and their potential in diagnostics. TrAC, Trends Anal. Chem. 2013, 44:121-130.
68. Gao Z.Q., Yu Y.H. Direct labeling microRNA with an electrocatalytic moiety and its application in ultrasensitive microRNA assays. Biosens. Bioelectron. 2007, 22:933-940.
69. Hilt J.Z. Nanotechnology and biomimetic methods in therapeutics: molecular scale control with some help from nature. Adv. Drug Deliv. Rev. 2004, 56:1533-1536.
70. Venkatesan B.M., Bashir R. Nanopore sensors for nucleic acid analysis. Nat. Nanotechnol. 2011, 6:615-624.
71. Uzumcu A., Tekguc M., Sevli S., Bayrak O.F., Ozen M. The role of microRNA (miRNA)S as a novel tool in cancer diagnosis and therapy. IUBMB Life 2009, 61:298.
72. Zhang Y., Wang Z.J., Gemeinhart R.A. Progress in microRNA delivery. J. Control. Release 2013, 172:962-974.
73. Watts J.K., Corey D.R. Silencing disease genes in the laboratory and the clinic. J. Pathol. 2012, 226:365-379.
74. Wurdinger T., Costa F.F. Molecular therapy in the microRNA era. Pharmacogenomics J. 2007, 7:297-304.
75. Kanasty R., Dorkin J.R., Vegas A., Anderson D. Delivery materials for siRNA therapeutics. Nat. Mater. 2013, 12:967-977.
76. Vickers K.C., Remaley A.T. Lipid-based carriers of microRNAs and intercellular communication. Curr. Opin. Lipidol. 2012, 23:91-97.
77. Pirollo K.F., Chang E.H. Targeted delivery of small interfering RNA: approaching effective cancer therapies. Cancer Res. 2008, 68:1247-1250.
78. Gao Y., Liu X.L., Li X.R. Research progress on siRNA delivery with nonviral carriers. Int. J. Nanomedicine 2011, 6:1017-1025.
79. Kim T.H., Lee S., Chen X. Nanotheranostics for personalized medicine. Expert. Rev. Mol. Diagn. 2013, 13:257-269.
80. Etzioni R., Urban N., Ramsey S., McIntosh M., Schwartz S., Reid B., Radich J., Anderson G., Hartwell L. The case for early detection. Nat. Rev. Cancer 2003, 3:243-252.
81. Mura S., Couvreur P. Nanotheranostics for personalized medicine. Adv. Drug Deliv. Rev. 2012, 64:1394-1416.
82. Conde J., de la Fuente J.M., Baptista P.V. Nanomaterials for reversion of multidrug resistance in cancer: a new hope for an old idea?. Front. Pharmacol. 2013, 4:134.
83. Lammers T., Aime S., Hennink W.E., Storm G., Kiessling F. Theranostic nanomedicine. Acc. Chem. Res. 2011, 44:1029-1038.
84. Ma X., Zhao Y., Liang X.J. Theranostic nanoparticles engineered for clinic and pharmaceutics. Acc. Chem. Res. 2011, 44:1114-1122.
85. Sanvicens N., Marco M.P. Multifunctional nanoparticles-properties and prospects for their use in human medicine. Trends Biotechnol. 2008, 26:425-433.
86. Cho E.C., Glaus C., Chen J., Welch M.J., Xia Y. Inorganic nanoparticle-based contrast agents for molecular imaging. Trends Mol. Med. 2010, 16:561-573.
87. Minelli C., Lowe S.B., Stevens M.M. Engineering nanocomposite materials for cancer therapy. Small 2010, 6:2336-2357.
88. Kim S.S., Garg H., Joshi A., Manjunath N. Strategies for targeted nonviral delivery of siRNAs in vivo. Trends Mol. Med. 2009, 15:491-500.
89. Akhtar S., Benter I.F. Nonviral delivery of synthetic siRNAs in vivo. J. Clin. Invest. 2007, 117:3623-3632.
90. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat. Rev. Cancer 2005, 5:161-171.
91. Doria G., Conde J., Veigas B., Giestas L., Almeida C., Assuncao M., Rosa J., Baptista P.V. Noble metal nanoparticles for biosensing applications. Sensors (Basel) 2012, 12:1657-1687.
92. Rayburn E.R., Zhang R. Antisense, RNAi, and gene silencing strategies for therapy: mission possible or impossible?. Drug Discov. Today 2008, 13:513-521.
93. Toub N., Malvy C., Fattal E., Couvreur P. Innovative nanotechnologies for the delivery of oligonucleotides and siRNA. Biomed. Pharmacother. 2006, 60:607-620.
94. Dobrovolskaia M.A., McNeil S.E. Immunological properties of engineered nanomaterials. Nat. Nanotechnol. 2007, 2:469-478.
95. Bhadra D., Bhadra S., Jain P., Jain N.K. Pegnology: a review of PEG-ylated systems. Pharmazie 2002, 57:5-29.
96. Hao L.L., Patel P.C., Alhasan A.H., Giljohann D.A., Mirkin C.A. Nucleic acid-gold nanoparticle conjugates as mimics of microRNA. Small 2011, 7:3158-3162.
97. Ghosh R., Singh L.C., Shohet J.M., Gunaratne P.H. A gold nanoparticle platform for the delivery of functional microRNAs into cancer cells. Biomaterials 2013, 34:807-816.
98. Kim J.H., Yeom J.H., Ko J.J., Han M.S., Lee K., Na S.Y., Bae J. Effective delivery of anti-miRNA DNA oligonucleotides by functionalized gold nanoparticles. J. Biotechnol. 2011, 155:287-292.
99. Crew E., Rahman S., Razzak-Jaffar A., Mott D., Kamundi M., Yu G., Tchah N., Lee J., Bellavia M., Zhong C.J. MicroRNA conjugated gold nanoparticles and cell transfection. Anal. Chem. 2012, 84:26-29.
100. Kim J.K., Choi K.J., Lee M., Jo M.H., Kim S. Molecular imaging of a cancer-targeting theragnostics probe using a nucleolin aptamer- and microRNA-221 molecular beacon-conjugated nanoparticle. Biomaterials 2012, 33:207-217.
101. Yigit M.V., Ghosh S.K., Kumar M., Petkova V., Kavishwar A., Moore A., Medarova Z. Context-dependent differences in miR-10b breast oncogenesis can be targeted for the prevention and arrest of lymph node metastasis. Oncogene 2013, 32:1530-1538.
102. Natarajan A., Venugopal S., DeNardo S., Zern M., Azar Fred S. Breast cancer targeting novel microRNA-nanoparticles for imaging. Proc. of SPIE. Multimodal Biomedical Imaging IV 2009, Xavier Intes.
103. Tivnan A., Orr W.S., Gubala V., Nooney R., Williams D.E., McDonagh C., Prenter S., Harvey H., Domingo-Fernandez R., Bray I.M., Piskareva O., Ng C.Y., Lode H.N., Davidoff A.M., Stallings R.L. Inhibition of neuroblastoma tumor growth by targeted delivery of microRNA-34a using anti-disialoganglioside GD(2) coated nanoparticles. PLoS One 2012, 7.
104. Yang H.W., Huang C.Y., Lin C.W., Liu H.L., Huang C.W., Liao S.S., Chen P.Y., Lu Y.J., Wei K.C., Ma C.C. Gadolinium-functionalized nanographene oxide for combined drug and microRNA delivery and magnetic resonance imaging. Biomaterials 2014, 35:6534-6542.
105. Wu Y., Crawford M., Yu B., Mao Y.C., Nana-Sinkam S.P., Lee L.J. MicroRNA delivery by cationic lipoplexes for lung cancer therapy. Mol. Pharm. 2011, 8:1381-1389.
106. Chen Y.C., Zhu X.D., Zhang X.J., Liu B., Huang L. Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy. Mol. Ther. 2010, 18:1650-1656.
107. Akao Y., Nakagawa Y., Hirata I., Iio A., Itoh T., Kojima K., Nakashima R., Kitade Y., Naoe T. Role of anti-oncomirs miR-143 and-145 in human colorectal tumors. Cancer Gene Ther. 2010, 17:398-408.
108. Takahashi M., Yamada N., Hatakeyama H., Murata M., Sato Y., Minakawa N., Harashima H., Matsuda A. In vitro optimization of 2'-OMe-4'-thioribonucleoside-modified anti-microRNA oligonucleotides and its targeting delivery to mouse liver using a liposomal nanoparticle. Nucleic Acids Res. 2013, 41:10659-10667.
109. Trang P., Wiggins J.F., Daige C.L., Cho C., Omotola M., Brown D., Weidhaas J.B., Bader A.G., Slack F.J. Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol. Ther. 2011, 19:1116-1122.
110. Piao L.Z., Zhang M.C., Datta J., Xie X.J., Su T.Z., Li H., Teknos T.N., Pan Q.T. Lipid-based nanoparticle delivery of pre-miR-107 inhibits the tumorigenicity of head and neck squamous cell carcinoma. Mol. Ther. 2012, 20:1261-1269.
111. Rai K., Takigawa N., Ito S., Kashihara H., Ichihara E., Yasuda T., Shimizu K., Tanimoto M., Kiura K. Liposomal delivery of microRNA-7-expressing plasmid overcomes epidermal growth factor receptor tyrosine kinase inhibitor-resistance in lung cancer cells. Mol. Cancer Ther. 2011, 10:1720-1727.
112. Zhang M., Zhou X., Wang B., Yung B.C., Lee L.J., Ghoshal K., Lee R.J. Lactosylated gramicidin-based lipid nanoparticles (Lac-GLN) for targeted delivery of anti-miR-155 to hepatocellular carcinoma. J. Control. Release 2013, 168:251-261.
113. Takeshita F., Patrawala L., Osaki M., Takahashi R., Yamamoto Y., Kosaka N., Kawamata M., Kelnar K., Bader A.G., Brown D., Ochiya T. Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes. Mol. Ther. 2010, 18:181-187.
114. Tazawa H., Tsuchiya N., Izumiya M., Nakagama H. Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:15472-15477.
115. Ibrahim A.F., Weirauch U., Thomas M., Grunweller A., Hartmann R.K., Aigner A. MicroRNA replacement therapy for miR-145 and miR-33a is efficacious in a model of colon carcinoma. Cancer Res. 2011, 71:5214-5224.
116. Matsuyama H., Suzuki H.I., Nishimori H., Noguchi M., Yao T., Komatsu N., Mano H., Sugimoto K., Miyazono K. miR-135b mediates NPM-ALK-driven oncogenicity and renders IL-17-producing immunophenotype to anaplastic large cell lymphoma. Blood 2011, 118:6881-6892.
117. Ren Y., Zhou X., Mei M., Yuan X.B., Han L., Wang G.X., Jia Z.F., Xu P., Pu P.Y., Kang C.S. MicroRNA-21 inhibitor sensitizes human glioblastoma cells U251 (PTEN-mutant) and LN229 (PTEN-wild type) to taxol. BMC Cancer 2010, 10.
118. Ren Y., Kang C.S., Yuan X.B., Zhou X., Xu P., Han L., Wang G.X., Jia Z.F., Zhong Y., Yu S.Z., Sheng J., Pu P.Y. Co-delivery of as-miR-21 and 5-FU by poly(amidoamine) dendrimer attenuates human glioma cell growth in vitro. J. Biomater. Sci. Polym. Ed. 2010, 21:303-314.
119. Liu Y.C., Zhao L.M., Li D.M., Yin Y., Zhang C.Y., Li J., Zhang Y.J. Microvesicle-delivery miR-150 promotes tumorigenesis by up-regulating VEGF, and the neutralization of miR-150 attenuate tumor development. Protein Cell 2013, 4:932-941.
120. Ohno S., Takanashi M., Sudo K., Ueda S., Ishikawa A., Matsuyama N., Fujita K., Mizutani T., Ohgi T., Ochiya T., Gotoh N., Kuroda M. Systemically injected exosomes targeted to EGFR deliver antitumor microRNA to breast cancer cells. Mol. Ther. 2013, 21:185-191.
121. Conde J., Doria G., Baptista P. Noble metal nanoparticles applications in cancer. J. Drug Deliv. 2012, 2012:751075.
122. Sperling R.A., Rivera G.P., Zhang F., Zanella M., Parak W.J. Biological applications of gold nanoparticles. Chem. Soc. Rev. 2008, 37:1896-1908.
123. Conde J., Rosa J., Baptista P.V. Gold-nanobeacons as a theranostic system for the detection and inhibition of specific genes. Protocol exchange. Nat. Publ. Group 2013, 10.1038/protex.2013.088.
124. Conde J., Larguinho M., Cordeiro A., Raposo L.R., Costa P.M., Santos S., Diniz M.S., Fernandes A.R., Baptista P.V. Gold-nanobeacons for gene therapy: evaluation of genotoxicity, cell toxicity and proteome profiling analysis. Nanotoxicology 2013, 5:521-532.
125. Rosa J., Conde J., de la Fuente J.M., Lima J.C., Baptista P.V. Gold-nanobeacons for real-time monitoring of RNA synthesis. Biosens. Bioelectron. 2012, 36:161-167.
126. Muthiah M., Park I.K., Cho C.S. Nanoparticle-mediated delivery of therapeutic genes: focus on miRNA therapeutics. Expert Opin. Drug Deliv. 2013, 10:1259-1273.
127. Park T.G., Jeong J.H., Kim S.W. Current status of polymeric gene delivery systems. Adv. Drug Deliv. Rev. 2006, 58:467-486.
128. Xue W., Dahlman J.E., Tammela T., Khan O.F., Sood S., Dave A., Cai W., Chirino L.M., Yang G.R., Bronson R., Crowley D.G., Sahay G., Schroeder A., Langer R., Anderson D.G., Jacks T. Small RNA combination therapy for lung cancer. Proc. Natl. Acad. Sci. U. S. A. 2014, 111:3553-3561.
129. Hsu S.H., Yu B., Wang X., Lu Y., Schmidt C.R., Lee R.J., Lee L.J., Jacob S.T., Ghoshal K. Cationic lipid nanoparticles for therapeutic delivery of siRNA and miRNA to murine liver tumor. Nanomedicine 2013, 9:1169-1180.
130. Choi K.Y., Silvestre O.F., Huang X., Min K.H., Howard G.P., Hida N., Jin A.J., Carvajal N., Lee S.W., Hong J.I., Chen X. Versatile RNA interference nanoplatform for systemic delivery of RNAs. ACS Nano 2014, 8:4559-4570.
131. Lv H.T., Zhang S.B., Wang B., Cui S.H., Yan J. Toxicity of cationic lipids and cationic polymers in gene delivery. J. Control. Release 2006, 114:100-109.
132. Liu X.Q., Song W.J., Sun T.M., Zhang P.Z., Wang J. Targeted delivery of antisense inhibitor of miRNA for antiangiogenesis therapy using cRGD-functionalized nanoparticles. Mol. Pharm. 2011, 8:250-259.
133. Burgess P., Hutt P.B., Farokhzad O.C., Langer R., Minick S., Zale S. On firm ground: IP protection of therapeutic nanoparticles. Nat. Biotechnol. 2010, 28:1267-1271.
134. Gil P.R., Parak W.J. Composite nanoparticles take aim at cancer. ACS Nano 2008, 2:2200-2205.
135. Whitehead K.A., Langer R., Anderson D.G. Knocking down barriers: advances in siRNA delivery. Nat. Rev. Drug Discov. 2009, 8:129-138.
136. Haussecker D. The business of RNAi therapeutics in 2012. Mol. Ther.-Nucleic Acids 2012, 1.
137. Dong Y.Z., Love K.T., Dorkin J.R., Sirirungruang S., Zhang Y.L., Chen D.L., Bogorad R.L., Yin H., Chen Y., Vegas A.J., Alabi C.A., Sahay G., Olejnik K.T., Wang W.H., Schroeder A., Lytton-Jean A.K.R., Siegwart D.J., Akinc A., Barnes C., Barros S.A., Carioto M., Fitzgerald K., Hettinger J., Kumar V., Novobrantseva T.I., Qin J.N., Querbes W., Koteliansky V., Langer R., Anderson D.G. Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates. Proc. Natl. Acad. Sci. U. S. A. 2014, 111:3955-3960.
138. Segovia N., Pont M., Oliva N., Ramos V., Borros S., Artzi N. Hydrogel doped with nanoparticles for local sustained release of siRNA in breast cancer. Adv. Health Mater. 2014, [Epub ahead of print].
139. Artzi N., Shazly T., Baker A.B., Bon A., Edelman E.R. Aldehyde-amine chemistry enables modulated biosealants with tissue-specific adhesion. Adv. Mater. 2009, 21:3399-3403.
140. Kluge J.A., Mauck R.L. Synthetic/biopolymer nanofibrous composites as dynamic tissue engineering scaffolds. Biomed Appl Polym. Nanofibers 2012, 246:101-130.
141. Restani R.B., Morgado P.I., Ribeiro M.P., Correia I.J., Aguiar-Ricardo A., Bonifacio V.D.B. Biocompatible polyurea dendrimers with pH-dependent fluorescence. Angew. Chem. Int. Ed. 2012, 51:5162-5165.
142. Dang J.M., Leong K.W. Natural polymers for gene delivery and tissue engineering. Adv. Drug Deliv. Rev. 2006, 58:487-499.
143. Dawson E., Mapili G., Erickson K., Taqvi S., Roy K. Biomaterials for stem cell differentiation. Adv. Drug Deliv. Rev. 2008, 60:215-228.
144. Ekenseair A.K., Kasper F.K., Mikos A.G. Perspectives on the interface of drug delivery and tissue engineering. Adv. Drug Deliv. Rev. 2013, 65:89-92.
145. O'Brien F.J. Biomaterials & scaffolds for tissue engineering. Mater. Today 2011, 14:88-95.
146. Lasagna-Reeves C., Gonzalez-Romero D., Barria M.A., Olmedo I., Clos A., Sadagopa Ramanujam V.M., Urayama A., Vergara L., Kogan M.J., Soto C. Bioaccumulation and toxicity of gold nanoparticles after repeated administration in mice. Biochem. Biophys. Res. Commun. 2010, 393:649-655.
147. Conde J., Tian F., Baptista P.V., de la Fuente J.M. Multifunctional gold nanocarriers for cancer theranostics - from bench to bedside and back again?. Nano-oncologicals: New Targeting and Delivery Approaches 2014, Springer International Publishing AG, (in press). M.G. Fuentes (Ed.).
148. Sun X., Rossin R., Turner J.L., Becker M.L., Joralemon M.J., Welch M.J., Wooley K.L. An assessment of the effects of shell cross-linked nanoparticle size, core composition, and surface PEGylation on in vivo biodistribution. Biomacromolecules 2005, 6:2541-2554.
149. Bellucci S. Nanoparticles and Nanodevices in Biological Applications 2009, Springer.
150. Shenhar R., Rotello V.M. Nanoparticles: scaffolds and building blocks. Acc. Chem. Res. 2003, 36:549-561.